KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Convertible Debt (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Convertible Debt for 14 consecutive years, with $311.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Convertible Debt changed 0.46% year-over-year to $311.7 million, compared with a TTM value of $311.7 million through Dec 2025, changed 0.46%, and an annual FY2025 reading of $311.7 million, changed 0.46% over the prior year.
  • Convertible Debt was $311.7 million for Q4 2025 at Travere Therapeutics, roughly flat from $311.4 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $378.1 million in Q2 2024 and bottomed at $218.1 million in Q1 2021.
  • Average Convertible Debt over 5 years is $325.8 million, with a median of $343.0 million recorded in 2022.
  • The sharpest move saw Convertible Debt soared 71.65% in 2022, then decreased 17.75% in 2025.
  • Year by year, Convertible Debt stood at $226.6 million in 2021, then skyrocketed by 65.74% to $375.5 million in 2022, then rose by 0.46% to $377.3 million in 2023, then dropped by 17.75% to $310.3 million in 2024, then rose by 0.46% to $311.7 million in 2025.
  • Business Quant data shows Convertible Debt for TVTX at $311.7 million in Q4 2025, $311.4 million in Q3 2025, and $311.0 million in Q2 2025.